These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37844322)

  • 21. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings.
    Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Williams AJ; Ng W; Connor S
    Intern Med J; 2021 May; 51(5):739-745. PubMed ID: 31589357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial.
    Bossuyt P; Pouillon L; Claeys S; D'Haens S; Hoefkens E; Strubbe B; Marichal D; Peeters H
    J Crohns Colitis; 2022 Feb; 16(2):199-206. PubMed ID: 34297099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort.
    Azzam N; Aljebreen A; Alharbi O; Charabaty A; Alanazi M; Alkuwaykibi N; Alfaraidi J; Bashamil A; Almansour T; Almadi M
    Arab J Gastroenterol; 2021 Mar; 22(1):66-72. PubMed ID: 33632623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.
    Dave MB; Dherai AJ; Desai DC; Mould DR; Ashavaid TF
    Eur J Clin Pharmacol; 2021 Jan; 77(1):55-62. PubMed ID: 32803288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.
    Huoponen S; Eberl A; Räsänen P; Roine RP; Sipponen T; Arkkila P; Blom M
    Medicine (Baltimore); 2020 Jan; 99(2):e18723. PubMed ID: 31914087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
    Curci D; Lucafò M; Cifù A; Bramuzzo M; Martelossi S; Favretto D; De Pellegrin F; Fabris M; Vascotto F; Naviglio S; Ventura A; Stocco G; Decorti G
    J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Hofmekler T; Bertha M; McCracken C; Martineau B; McKinnon E; Schoen BT; McElhanon BO; Tenjarla G; Kugathasan S; Sauer CG
    J Pediatr Gastroenterol Nutr; 2017 Apr; 64(4):580-585. PubMed ID: 28079601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P010 Precision Dosing Tool Forecasts Trough Infliximab and Associates With Disease Status in Inflammatory Bowel Diseases.
    Dervieux T; Primas C; Panetta J; Mould D; Eser A; Reinisch W
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S3. PubMed ID: 37461930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.
    Lega S; Phan BL; Rosenthal CJ; Gordon J; Haddad N; Pittman N; Benkov KJ; Dubinsky MC
    Inflamm Bowel Dis; 2019 Jan; 25(1):134-141. PubMed ID: 29868777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease.
    Theodoraki E; Orfanoudaki E; Foteinogiannopoulou K; Koutroubakis IE
    Inflamm Bowel Dis; 2018 May; 24(6):1266-1271. PubMed ID: 29718260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
    Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
    Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients.
    Veerappan SG; Healy M; Walsh B; O'Morain CA; Daly JS; Ryan BM
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1335-44. PubMed ID: 27508327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.
    Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR
    Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease.
    Choi SY; Kang B; Lee JH; Choe YH
    Gut Liver; 2017 Jan; 11(1):55-61. PubMed ID: 27609485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. INDUCTION THERAPEUTIC DRUG MONITORING REGIMEN WITH INFLIXIMAB: A SIMPLIFIED EVIDENCE-BASED ALGORITHM FOR INFLAMMATORY BOWEL DISEASE.
    Queiroz NSF; Teixeira FV; Parra RS; Kotze PG
    Arq Gastroenterol; 2020; 57(4):507-510. PubMed ID: 33331484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
    Merras-Salmio L; Kolho KL
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.